scispace - formally typeset
Open AccessJournal ArticleDOI

Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative

TLDR
Recommendations for the diagnosis and treatment of JIA-associated uveitis have been formulated by an evidence-informed consensus process to suggest a standard of care for Jia-associated Uveitis patients throughout Europe.
Abstract
Background In 2012, a European initiative called Single Hub and Access point for pediatric Rheumatology in Europe (SHARE) was launched to optimise and disseminate diagnostic and management regimens in Europe for children and young adults with rheumatic diseases. Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children and uveitis is possibly its most devastating extra-articular manifestation. Evidence-based guidelines are sparse and management is mostly based on physicians’ experience. Consequently, treatment practices differ widely, within and between nations. Objectives To provide recommendations for the diagnosis and treatment of JIA-associated uveitis. Methods Recommendations were developed by an evidence-informed consensus process using the European League Against Rheumatism standard operating procedures. A committee was constituted, consisting of nine experienced paediatric rheumatologists and three experts in ophthalmology from Europe. Recommendations derived from a validated systematic literature review were evaluated by an Expert Committee and subsequently discussed at two consensus meetings using nominal group techniques. Recommendations were accepted if >80% agreement was reached (including all three ophthalmologists). Results In total, 22 recommendations were accepted (with >80% agreement among experts): 3 on diagnosis, 5 on disease activity measurements, 12 on treatment and 2 on future recommendations. Conclusions The SHARE initiative aims to identify best practices for treatment of patients suffering from JIA-associated uveitis. Within this remit, recommendations for the diagnosis and treatment of JIA-associated uveitis have been formulated by an evidence-informed consensus process to suggest a standard of care for JIA-associated uveitis patients throughout Europe.

read more

Citations
More filters
Journal ArticleDOI

JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis.

TL;DR: JAK inhibitors may provide a new valuable treatment option in the therapeutic armamentarium for patients affected with JIA-associated uveitis, particularly in those refractory cases that are not adequately responding to conventional or biologic DMARDs.
Journal ArticleDOI

Juvenile idiopathic arthritis

TL;DR: This Primer by Martini and colleagues summarizes the epidemiology, pathophysiology, diagnosis and management of Juvenile idiopathic arthritis (JIA), the most common chronic inflammatory rheumatic condition of childhood, and reviews future research directions to improve patient care.
Journal ArticleDOI

Update on the epidemiology, risk factors and disease outcomes of juvenile idiopathic arthritis.

TL;DR: The need for adults with JIA to be seen as a distinct group in adult rheumatology practice is important for both service provision and outcome research.
Journal ArticleDOI

Juvenile idiopathic arthritis-associated uveitis.

TL;DR: Two randomised controlled trials of adalimumab in JIA-associated uveitis provide convincing evidence for the use of this biologic in patients who fail to respond adequately to methotrexate.
References
More filters
Journal ArticleDOI

Juvenile idiopathic arthritis: new insights into classification, measures of outcome, and pharmacotherapy.

TL;DR: This review focuses on recent advances in JIA, especially developments in its classification, validation of appropriate measures of holistic outcome, and the specific contribution of established and newer pharmacologic agents available for treating children and young people.
Journal ArticleDOI

Juvenile Idiopathic Arthritis

TL;DR: Etanercept offers a promising new alternative for patients with JIA who have persistently active arthritis despite treatment with methotrexate, and whether it can be administered safely for long periods of time to children.
Related Papers (5)